A randomized, double-blind, placebo-controlled trial of recombinant erythropoietin in treatment of the anemia of bronchopulmonary dysplasia.

A randomized, double-blind, placebo-controlled trial of recombinant erythropoietin in treatment of the anemia of bronchopulmonary dysplasia.
复制标题

重组促红细胞生成素治疗支气管肺发育不良贫血的随机、双盲、安慰剂对照试验。

DOI:
10.1016/s0022-3476(05)80401-9
复制
发表时间:
1993
期刊:
The Journal of pediatrics
影响因子:
--
通讯作者:
R. Christensen
R. Christensen
中科院分区:
--
文献类型:
--
作者:
R. Ohls;D. Hunter;R. Christensen

文献摘要

参考文献

被引文献

相似文献

由于支气管肺发育不良患者贫血的特征是血清中红细胞增多素浓度不适当地低,但体外红细胞系祖细胞对红细胞增多素的敏感性增加,我们推测给予人重组红细胞增多素将纠正这种贫血。15例支气管肺发育不良性贫血患儿随机分为两组,分别接受促红细胞生成素和安慰剂皮下注射治疗10天。评估网织红细胞计数、红细胞压积、血乳酸浓度、中性粒细胞计数、血小板计数、心率、需氧量、体重增加和输血次数的变化。在10例促红细胞生成素接受者(99±12日龄)中,红细胞压积值从0.325±0.006增加到0.381±0.013(平均值± SEM;p<0.005),网织红细胞计数从122±20增加到446±48×103/μl(p<0.005);乳酸值保持不变。在5名安慰剂接受者(91±12日龄)中,血细胞比容和网织红细胞计数保持不变,乳酸值从0.73±0.14增加到1.34±0.25 μmol/gm(p<0.05)。在治疗期后的30天内,一名促红细胞生成素接受者和四名安慰剂接受者接受了输血。其他测量变量在两组中保持不变。我们认为,红霉素是有效的治疗支气管肺发育不良性贫血。
Because anemia in patients with bronchopulmonary dysplasia is characterized by inappropriately low serum concentrations of erythropoletin but increased in vitro sensitivity of erythrold progenitors to erythropoletin, we speculated that administration of human recombinant erythropoletin would correct this anemia. Fifteen infants with the anemia of bronchopulmonary dysplasia were randomly assigned to recelve erythropoietin or placebo subcutaneously for 10 days. Changes in reticulocyte count, hematocrit, blood lactate concentration, neutrophil count, platelet count, heart rate, oxygen requirement, weight gain, and number of transfusions were assessed. In the 10 erythropoietin recipients (99±12 days of age), hematocrit values increased from 0.325±0.006 to 0.381±0.013 (mean ± SEM;p<0.005) and reticulocyte counts from 122±20 to 446±48×103/μl (p<0.005); lactate values remained unchanged. In the five placebo recipients (91±12 days of age), hematocrits and reticulocyte counts remained unchanged, and lactate values increased from 0.73±0.14 to 1.34±0.25 μmol/gm (p<0.05). During the 30 days after the treatment period, one erythropoietin recipient and four placebo recipients were given transfusions. Other measured variables remained unchanged in both groups. We conclude that erythropoletin is effective in treatment of the anemia of bronchopulmonary dysplasia.
对新生大鼠施用促红细胞生成素会导致中性粒细胞产生减少。
DOI: --
发表时间: 1991
期刊: Blood
影响因子: 20.3
作者:
Christensen,RD;Liechty,KW;Koenig,JM;Schibler,KR;Ohls,RK
通讯作者: Ohls,RK
重组促红细胞生成素治疗 Rh 溶血病晚期低再生性贫血。
DOI: --
发表时间: 1992
期刊: Pediatrics
影响因子: 8
作者:
Ohls,RK;Wirkus,PE;Christensen,RD
通讯作者: Christensen,RD
重组促红细胞生成素与红细胞输注治疗早产儿贫血的比较。
DOI: 10.1016/s0022-3476(05)80303-8
发表时间: 1991
期刊: The Journal of pediatrics
影响因子: --
作者:
Ohls,RK;Christensen,RD
通讯作者: Christensen,RD
一项随机试验,旨在制定 1 至 3 个月大贫血早产儿红细胞输注的标准。
DOI: --
发表时间: 1989
期刊: Journal of perinatology : official journal of the California Perinatal Association
影响因子: --
作者:
Ross,MP;Christensen,RD;Rothstein,G;Koenig,JM;Simmons,MA;Noble,NA;Kimura,RE
通讯作者: Kimura,RE
DOI: 10.1016/s0022-3476(88)80389-5
发表时间: 1988
期刊: The Journal of pediatrics
影响因子: --
作者:
Alverson,DC;Isken,VH;Cohen,RS
通讯作者: Cohen,RS